A genetic variant near GATA3 implicated in inherited susceptibility and etiology of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS)
ConclusionsRs17144046 located near GATA3 was significantly associated with BPH/LUTS in three independent populations, but did not reach a stringent GWAS significance level. Genetic variants of GATA3 may play a role in the inherited susceptibility and etiology of BPH/LUTS. Further research in this area is needed. (Source: The Prostate)
Source: The Prostate - June 28, 2017 Category: Urology & Nephrology Authors: Rong Na, Brian T. Helfand, Haitao Chen, Carly A. Conran, Susan E. Crawford, Simon W. Hayward, Teuvo L.J. Tammela, Judy Hoffman ‐Bolton, Siqun L. Zheng, Patrick C. Walsh, Johanna Schleutker, Elizabeth A. Platz, William B. Isaacs, Jianfeng Xu Tags: ORIGINAL ARTICLE Source Type: research
Issue Information ‐ Editorial Board
(Source: The Prostate)
Source: The Prostate - June 28, 2017 Category: Urology & Nephrology Tags: ISSUE INFORMATION Source Type: research
Dose considerations for anti ‐cancer drugs in metastatic prostate cancer
Despite a growing number of treatment options, metastatic castrate resistant prostate cancer remains almost universally fatal. Dose individualization ensures patients receive the maximal benefit from each line of treatment potentially leading to improved outcomes, a reduction in quality of life impairment and minimization of premature cessation for avoidable toxicity. Herein, we review drug‐specific issues that may be associated with unexpected or unrecognized variations in drug systemic exposure despite the use of protocol doses. In particular, we discuss the potential for under‐exposure of docetaxel and cabazitaxel; ...
Source: The Prostate - June 26, 2017 Category: Urology & Nephrology Authors: Megan Crumbaker, Howard Gurney Tags: REVIEW ARTICLE Source Type: research
Inhibition of microRNA ‐500 has anti‐cancer effect through its conditional downstream target of TFPI in human prostate cancer
ConclusionMiR‐500 may be a potential biomarker and molecular target in prostate cancer. TFPI may conditionally regulate prostate cancer in miR‐500‐downregualted prostate cancer cells. (Source: The Prostate)
Source: The Prostate - June 20, 2017 Category: Urology & Nephrology Authors: Bing Cai, Wei Chen, Yue Pan, Hongde Chen, Yirong Zhang, Zhiliang Weng, Yeping Li Tags: ORIGINAL ARTICLE Source Type: research
Adult prostatic sarcoma: A contemporary multicenter Rare Cancer Network study
ConclusionAdult PS has a poor prognosis. Locally advanced tumors have poor LC and OS rates. Curative RT should be considered part of the multidisciplinary approach to PS. (Source: The Prostate)
Source: The Prostate - June 8, 2017 Category: Urology & Nephrology Authors: Berardino De Bari, Bradley Stish, Mark Wayne Ball, Yacob Habboush, Paul Sargos, Marco Krengli, Alberto Bossi, Armando Stabile, Claudio Sole Pesutic, La ëtitia Lestrade, Robert Jan Smeenk, Barbara Alicja Jereczek‐Fossa, Zilli Thomas, Gilles Créhange, F Tags: ORIGINAL ARTICLE Source Type: research
